Jazz Pharmaceuticals Acquires Actio Biosciences for $820M to Expand Epilepsy Portfolio
On September 15, Jazz Pharmaceuticals (NASDAQ:JAZZ) acquired privately held Actio Biosciences in a deal valued at $820 million upfront. The acquisition adds ABS-1230, an experimental drug for KCNT1-related epilepsy—a rare and difficult-to-treat form of the disease—to Jazz’s portfolio. Early clinical trials showed promising results with seizure reduction in children, while preclinical data suggest broad efficacy across different mutations. The deal follows a strong financial performance by Jazz, which reported record second-quarter revenue of $1.2 billion on August 3 and raised its full-year guidance to between $4.6 billion and $4.75 billion. The company's growth is being driven by multiple products including Xywav, Epidiolex, Zepzelca, and the recently FDA-designated Breakthrough Therapy drug Zanidatamab. However, Jazz’s acquisition strategy comes with financial risks. It already carries significant long-term debt of $4.4 billion as of June 30, and its cash reserves were at $2.2 billion—meaning Actio represents a large portion of available liquidity.
Tickers: $JAZZ
Topics: Corporate Strategy Epilepsy Drug Development Pharmaceuticals